Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Hyperuricemia Stories

2010-05-20 07:00:00

NEW YORK, May 20 /PRNewswire/ -- The Gout & Uric Acid Education Society (GUAES) announced today that new survey results reveal that only 1 in 4 (28 percent) of Americans believe that gout, a painful and potentially debilitating form of arthritis that affects 5 million Americans annually, can have a major negative impact on overall health and wellbeing. Yet, if left untreated the chronic health condition can progress to the point of being debilitating, with increased frequency of...

2010-05-13 07:00:00

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present additional data from its completed Phase 2a and Phase 2b monotherapy studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy on June 18th and 19th. The Company will also present additional RDEA594 and allopurinol...

2010-05-07 07:30:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the first quarter ended March 31, 2010. "We are pleased to have accomplished a number of very important objectives since our last quarterly update," commented Barry D. Quart, PharmD,...

2010-03-31 15:01:00

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd...

2010-03-30 13:53:53

Gout incidence lower in women than men, says 52-year follow-up study Researchers from Boston University School of Medicine found that women with serum uric acid levels over 5 mg/dl had a significantly lower risk of developing gout than men. This study, the first to examine the relationship between uric acid levels and gout risk in women, also evaluated purported risk factors for gout and found that increasing age, obesity, hypertension, alcohol use, and diuretic use to be among leading...

2010-03-01 09:10:00

EXTON, Pa., March 1 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrends(®): Gout and Hyperuricemia publication. The report is based on responses to online surveys completed by 120 Rheumatologists and 57 Primary Care Physicians in the US who are managing a high number of patients with gout. This syndicated report provides comprehensive insight into how physicians classify patients with gout, how treatment is...

2010-01-07 07:30:00

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from the second panel of a Phase 1 drug-drug interaction and pharmacodynamic study of RDEA594 in combination with febuxostat (Uloric®, Takeda Pharmaceutical Company Limited;...

2009-12-01 07:00:00

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This randomized, placebo-controlled study in normal healthy volunteers with baseline...

2009-11-06 07:00:00

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO) "Since our last quarterly update, we have confirmed the...

2009-10-19 12:44:50

Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment. A subset of subjects from the CONFIRMS trial who received prior...


Latest Hyperuricemia Reference Libraries

45_cf9ebc73b3f1a13d4b11b52db1780092
2008-05-22 12:47:07

The Dalmatian is a coach dog which is easily recognized for its unique spotted coat. This ancient breed has been used as a guard dog, bird dog, trail hound, retriever, and most importantly a coach or carriage dog. The Dalmatian was once used to run in attendance on a coach. This ability was eventually transferred to its career as a firehouse dog. The Dalmatian once ran in front of horse-drawn fire carts to help clear a path for them as well as guide them to fires. The Dalmatian is a...

More Articles (1 articles) »